Paul J. Diaz
CIK: 0001194247
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- Nov 1, 2026MRK
Merck & Co., Inc.
Award(A)DirectPhantom Stock
613 shares at avg. $149.52- - Jul 28, 2026CNC
CENTENE CORP
Award(A)Direct2.8K shares- - Mar 24, 2025MYGN
MYRIAD GENETICS INC
Tax Payment(F)Direct18.3K shares at avg. $9.98$183K - Mar 24, 2025MYGN
MYRIAD GENETICS INC
Tax Payment(F)Direct26.8K shares at avg. $9.98$268K - Mar 22, 2025MYGN
MYRIAD GENETICS INC
Tax Payment(F)Direct19.9K shares at avg. $10.01$199K - Mar 22, 2025MYGN
MYRIAD GENETICS INC
Tax Payment(F)Direct52.7K shares at avg. $10.01$527K - Mar 15, 2025MYGN
MYRIAD GENETICS INC
Tax Payment(F)Direct30.1K shares at avg. $10.07$303K - Mar 14, 2025MYGN
MYRIAD GENETICS INC
Tax Payment(F)Direct37.6K shares at avg. $10.07$378K - Feb 7, 2025MYGN
MYRIAD GENETICS INC
Award(A)Direct114.8K shares- - Oct 11, 2024MYGN
MYRIAD GENETICS INC
Sale(S)Direct15K shares at avg. $22.93$344K - Sep 11, 2024MYGN
MYRIAD GENETICS INC
Sale(S)Direct15K shares at avg. $26.72$401K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Nov 1, 2026 |  MRK Merck & Co., Inc. | Award(A) Phantom Stock | 613 | $149.52 | - | Direct |
| Jul 28, 2026 |  CNC CENTENE CORP | Award(A) | 2,771 | - | $0 | Direct |
| Mar 24, 2025 |  MYGN MYRIAD GENETICS INC | Tax Payment(F) | 18,312 | $9.98 | $182,754 | Direct |
| Mar 24, 2025 | MYGN MYRIAD GENETICS INC | Tax Payment(F) | 26,827 | $9.98 | $267,733 | Direct |
| Mar 22, 2025 | MYGN MYRIAD GENETICS INC | Tax Payment(F) | 19,859 | $10.01 | $198,789 | Direct |
| Mar 22, 2025 | MYGN MYRIAD GENETICS INC | Tax Payment(F) | 52,682 | $10.01 | $527,347 | Direct |
| Mar 15, 2025 | MYGN MYRIAD GENETICS INC | Tax Payment(F) | 30,118 | $10.07 | $303,288 | Direct |
| Mar 14, 2025 | MYGN MYRIAD GENETICS INC | Tax Payment(F) | 37,564 | $10.07 | $378,269 | Direct |
| Feb 7, 2025 | MYGN MYRIAD GENETICS INC | Award(A) | 114,828 | - | - | Direct |
| Oct 11, 2024 | MYGN MYRIAD GENETICS INC | Sale(S) | 15,000 | $22.93 | $343,950 | Direct |
| Sep 11, 2024 | MYGN MYRIAD GENETICS INC | Sale(S) | 15,000 | $26.72 | $400,800 | Direct |
1-11 of 11 transactions
About DIAZ PAUL J
DIAZ PAUL J (SEC CIK 0001194247) files insider reports with the SEC as Director of Merck & Co., Inc. (MRK), Director of CENTENE CORP (CNC) and President and CEO of MYRIAD GENETICS INC (MYGN).
Signal8 holds 10 ownership filings by DIAZ PAUL J (2 Form 3, 8 Form 4), filed between Sep 12, 2024 and Nov 3, 2026. Those filings report 11 transactions, from Sep 11, 2024 to Nov 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on DIAZ PAUL J's filings is in RAHWAY, NJ.
Recent filings by DIAZ PAUL J
- Nov 1, 2026: Grant or award of MRK derivative securities (Form 4, code A).
- Jul 28, 2026: Grant or award of CNC shares (Form 4, code A).
- Mar 24, 2025: Tax withholdings of MYGN shares (2 lines, Form 4, code F).
- Mar 22, 2025: Tax withholdings of MYGN shares (2 lines, Form 4, code F).
- Mar 15, 2025: Tax withholding of MYGN shares (Form 4, code F).
Other insiders filing for Merck & Co., Inc. (MRK)
- Maraldo David R., EVP & Pres. MMD
- Seidman Christine E, Director
- Karsanbhai Surendralal Lanca, Director
- Coe Mary Ellen, Director
- Gupta Gaurav K, EVP, CIDO
- Guindo Chirfi, EVP, Access, Policy & Comms